Quantifying Preferences for CAR‐T Compared to Standard of Care as a First‐Line Treatment Among Patients With Multiple Myeloma
Open Access
- 19 July 2025
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 14 (14) , e71072
Abstract
Background: CAR‐T therapy is approved for the treatment of relapsed refractory multiple myeloma (MM) and is being studied for newly diagnosed MM (NDMM). The use of novel therapies in early‐line MM raises questions on the acceptability of upfront risks in exchange for extended relapse‐free periods without the treatment burden and limitations on daily activities associated with maintenance therapy.Methods: A discrete‐choice experiment was designed to elicit adults' preferences for hypothetical NDMM treatments. Benefits included time to relapse and reduction of treatment impact on daily activities. Severe adverse events were included to better understand patient preferences for rare but significant events.Results: On average, extending the time to relapse from 3 years (with moderate limitations on daily activities) to 5 years (without limitations) was three times more important than avoiding a 20% risk of hospitalization due to severe ICANS/CRS. Analysis revealed three latent preference classes: a benefit–risk trading class (65%), a class (28%) unwilling to accept increases in short‐term treatment‐related mortality, and a class (7%) that provided statistically uninformative data. For the trading class, for two additional relapse‐free years with minor limitations, all else equal, patients would accept up to a 30% risk of severe ICANS/CRS‐related hospitalization along with 0% risk of treatment‐related mortality. Alternatively, they would accept up to an 8% risk of treatment‐related mortality with a 0% risk of severe ICANS/CRS‐related hospitalization, or various combinations of lower AE risks.Conclusion: These results reveal preference heterogeneity among MM patients and the importance of effective communication about the benefits and risks of novel therapies.Keywords
Funding Information
- Janssen Research and Development
This publication has 28 references indexed in Scilit:
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple MyelomaNew England Journal of Medicine, 2021
- Alignment of preferences in the treatment of multiple myeloma – a discrete choice experiment of patient, carer, physician, and nurse preferencesBMC Cancer, 2020
- Analysis of Patient Preferences in Lung Cancer – Estimating Acceptable Tradeoffs Between Treatment Benefit and Side EffectsPatient Preference and Adherence, 2020
- Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)Blood Cancer Journal, 2020
- Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysisBlood Cancer Journal, 2020
- Discrete Choice Experiments in Health Economics: Past, Present and FuturePharmacoEconomics, 2018
- Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trialThe Lancet, 2017
- Validation of a Short, 3-Item Version of the Subjective Numeracy ScaleMedical Decision Making, 2015
- Patients’ preferences for treatment outcomes for advanced non-small cell lung cancer: A conjoint analysisLung Cancer, 2012
- Measuring Numeracy without a Math Test: Development of the Subjective Numeracy ScaleMedical Decision Making, 2007